|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400091512 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-29 18:32:02 |
|
注册时间: Date of Registration: |
2024-10-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
地西泮鼻喷雾剂用于儿童癫痫患者的安全性和有效性的真实世界研究 |
|
Public title: |
A Real World Study on the Safety and Efficacy of Diazepam Nasal Spray in Children with Epilepsy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
地西泮鼻喷雾剂用于儿童癫痫患者的安全性和有效性的真实世界研究 |
|
Scientific title: |
A Real World Study on the Safety and Efficacy of Diazepam Nasal Spray in Children with Epilepsy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郁莉斐 |
研究负责人: |
王艺 |
|
Applicant: |
Yulifei |
Study leader: |
Wangyi |
|
申请注册联系人电话: Applicant telephone: |
+86 138 1637 9016 |
研究负责人电话:
Study leader's |
+86 135 6476 6228 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yulifei7711@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yiwang@shmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市闵行区万源路399号 |
研究负责人通讯地址: |
上海市闵行区万源路399号 |
|
Applicant address: |
No. 399 Wanyuan Road, Minhang District, Shanghai |
Study leader's address: |
No. 399 Wanyuan Road, Minhang District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属儿科医院 |
||
|
Applicant's institution: |
Fudan University Affiliated Pediatric Hospital |
||
|
研究负责人所在单位: |
复旦大学附属儿科医院 |
||
|
Affiliation of the Leader: |
Fudan University Affiliated Pediatric Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
复儿伦审(2024)089号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属儿科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Pediatric Hospital Affiliated to Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-08-13 00:00:00 | ||
|
伦理委员会联系人: |
韩立远 |
||
|
Contact Name of the ethic committee: |
Hanliyuan |
||
|
伦理委员会联系地址: |
上海市闵行区万源路399号 |
||
|
Contact Address of the ethic committee: |
No. 399 Wanyuan Road, Minhang District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6493 1912 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属儿科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fudan University Affiliated Pediatric Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市闵行区万源路399号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 399 Wanyuan Road, Minhang District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
深圳市康哲药业有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shenzhen Kangzhe Pharmaceutical Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
癫痫 |
||||||||||||||||||||||
|
Target disease: |
Epilepsy |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
主要研究目的: 1.评估真实世界中,地西泮鼻喷雾剂急性治疗儿童癫痫患者癫痫频繁发作的安全性; 次要研究目的: 1.评估真实世界中,地西泮鼻喷雾剂急性治疗儿童癫痫患者癫痫频繁发作的有效性; 根据基线期收集的患者基线人口学、癫痫病史、癫痫发作频率、癫痫发作类型、用药方案、病因诊断等进行流行病学研究,分析中国诊疗环境下儿童癫痫患者出现丛集性癫痫发作的特征及风险因素。 |
||||||||||||||||||||||
|
Objectives of Study: |
Main study objectives: 1. To evaluate the safety of diazepam nasal spray in the acute treatment of frequent seizures in children with epilepsy in the real world; Secondary Study Objectives: 1. To evaluate the effectiveness of diazepam nasal spray in the acute treatment of frequent seizures in children with epilepsy in the real world; According to the baseline demography, epilepsy history, seizure frequency, seizure type, medication regimen and etiological diagnosis collected in the baseline period, epidemic studies were conducted to analyze the characteristics and risk factors of cluster seizures in Chinese children with epilepsy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.临床诊断为癫痫,在接受稳定的抗癫痫药物治疗方案期间(至少2个月稳定用药)仍出现癫痫频繁发作,入组前1年内有过至少6次癫痫发作,且前2个月有过至少1次癫痫发作;研究者认为需要接受地西泮鼻喷雾剂控制癫痫发作的患者; 2.年龄为2岁-18岁的儿童; 同意参与本研究,能够配合随访,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Epilepsy is clinically diagnosed, and frequent seizures still occur during stable antiepileptic drug regimen (stable medication for at least 2 months), at least 6 seizures within 1 year before enrollment, and at least 1 seizure in the first 2 months; Patients who, in the opinion of the investigator, required diazepam nasal spray for seizure control; 2. children aged two years and -18 years; Consent to participate in the study, ability to cooperate with follow-up, and signing of informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.患有较严重(不限于)感染、中毒、营养代谢障碍、内分泌疾病、五官、皮肤、呼吸和循环系统疾病、消化系统疾病、泌尿系统疾病、血液系统疾病、风湿免疫病或神经精神疾病等,研究者认为受试者存在安全隐患或者疾病本身或/和相关治疗会干扰试验进行与评估; 2.对地西泮或其他苯二氮?类药物以及试验药物辅料有过敏史或疑似过敏史; 3.有药物滥用、精神疾病或酗酒史,不能配合临床研究者; 4.急性闭角型青光眼患者; 研究者认为不适合参加研究的其他患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Have severe (but not limited to) infection, poisoning, nutrition and metabolism disorder, endocrine disease, five-organ disease, skin, respiratory and circulating system disease, digestive system disease, urinary system disease, hematological system disease, rheumatism immunization disease or neuropsychiatric disease, etc., and the investigator considers that the subject has potential safety hazard or the disease itself or/and relevant treatment will interfere with the trial; 2. History of allergy or suspected allergy to diazepam or other benzodiazepines and excipients of the investigational product; 3. He has a history of drug abuse, mental illness or alcoholism and cannot cooperate with the clinical investigator; 4. Acute angle closure glaucoma; Other patients who, in the opinion of the investigator, were not eligible to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-05-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-01 00:00:00 至 To 2026-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和电子采集和管理系统均涉及 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Both Case Record Form, CRF and Electronic Data Capture, EDC are involved in |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |